PBM
Psyence Biomedical Ltd. Common Shares
stock NASDAQ

This stock has been a wild ride thus far! It is down like most penny stocks this time of year, which also signals a potential good opportunity to buy at a discount.
Here are some upcoming catalysts for this stock and approximate time we might expect them:
1. iAccess Alpha Virtual Best Ideas Winter Conference presentation
—December 9–10, 2025 — Management presenting to investors. Already happened but may hear some updates or partnerships that resulted.
2. Arbli™ (losartan potassium oral suspension) commercial availability on BlinkRx
— Expected Q1 2026 — Expanded national patient access through BlinkRx platform. 
3. REZENOPY® (naloxone HCl nasal spray) commercial launch
— Planned Q1 2026 — Launch of high-dose naloxone product. 
4. Formulary expansion and GPO/PBM access updates for Arbli™
— Ongoing through early 2026 — Additional payor/coverage agreements could be announced incrementally. 
Financial / Reporting Catalysts
5. Q4 2025 / Full-Year 2025 Financial Results
— Likely early 2026 — Results including Arbli™ sales and guidance (exact date to be determined).
6. Q1 2026 Financial Results
— Likely mid-2026 — First quarterly results with REZENOPY® contributions.
Pipeline & Regulatory Catalysts (2026+)
7. IND/clinical start for SCN-104 (migraine injection pen)
— Potential in 2026 — If IND clearance occurs and clinical trials begin. 
8. IND submission for SCN-107 (long-acting analgesic)
— Potential in 2026 — Early development milestone before later-stage trials. 
9. SCN-104 Phase 1 results
— Projected 2026 — If the single-dose study in healthy adults proceeds on schedule. 
Corporate / Market Catalysts
10. Additional commercial partnerships or distribution agreements
— Possible throughout 2026 — e.g., new supply or patient access arrangements.
11. Capital markets activity (equity offerings under Form S-3)
— Ongoing through 2026 — Equity raises could support operations but also affect share count. 
12. Nasdaq compliance developments
— Ongoing — Continued compliance with listing rules may be a supportive sentiment event. 
Price prediction over the next 12 months goes up to $2.50. However the current 12 month high is $8.19.
Do your own research of course but felt this company was worth a solid discussion and some attention.

This stock has been a wild ride thus far! It is down like most penny stocks this time of year, which also signals a potential good opportunity to buy at a discount.
Here are some upcoming catalysts for this stock and approximate time we might expect them:
1. iAccess Alpha Virtual Best Ideas Winter Conference presentation
—December 9–10, 2025 — Management presenting to investors. Already happened but may hear some updates or partnerships that resulted.
2. Arbli™ (losartan potassium oral suspension) commercial availability on BlinkRx
— Expected Q1 2026 — Expanded national patient access through BlinkRx platform. 
3. REZENOPY® (naloxone HCl nasal spray) commercial launch
— Planned Q1 2026 — Launch of high-dose naloxone product. 
4. Formulary expansion and GPO/PBM access updates for Arbli™
— Ongoing through early 2026 — Additional payor/coverage agreements could be announced incrementally. 
Financial / Reporting Catalysts
5. Q4 2025 / Full-Year 2025 Financial Results
— Likely early 2026 — Results including Arbli™ sales and guidance (exact date to be determined).
6. Q1 2026 Financial Results
— Likely mid-2026 — First quarterly results with REZENOPY® contributions.
Pipeline & Regulatory Catalysts (2026+)
7. IND/clinical start for SCN-104 (migraine injection pen)
— Potential in 2026 — If IND clearance occurs and clinical trials begin. 
8. IND submission for SCN-107 (long-acting analgesic)
— Potential in 2026 — Early development milestone before later-stage trials. 
9. SCN-104 Phase 1 results
— Projected 2026 — If the single-dose study in healthy adults proceeds on schedule. 
Corporate / Market Catalysts
10. Additional commercial partnerships or distribution agreements
— Possible throughout 2026 — e.g., new supply or patient access arrangements.
11. Capital markets activity (equity offerings under Form S-3)
— Ongoing through 2026 — Equity raises could support operations but also affect share count. 
12. Nasdaq compliance developments
— Ongoing — Continued compliance with listing rules may be a supportive sentiment event. 
Price prediction over the next 12 months goes up to $2.50. However the current 12 month high is $8.19.
Do your own research of course but felt this company was worth a solid discussion and some attention.